Category Archives: Work

zoom
-

An Introspective on Immunotherapy

This Tuesday, the OncoSec team will play host to some of the most brilliant minds in immuno-oncology, with our highly anticipated symposium, “An Introspective on Immunotherapy: A Symposium on Intratumoral Therapy.” The event promises to be a notable high point during the week of J.P. Morgan’s annual healthcare conference, a week that has historically attracted the “who’s who” of the healthcare sector.

Continue reading

zoom
-

OncoSec, UCSF, and Merck Initiate a Landmark Phase IIb Combination Trial of Breakthrough Drug KEYTRUDA® And ImmunoPulse to Treat Metastatic Melanoma

OncoSec Medical is changing the cancer experience. Today changes the course of OncoSec as we announced a collaboration with the University of California San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of Merck’s anti-PD-1 drug, KEYTRUDA® (pembrolizumab), and OncoSec’s ImmunoPulse therapy (intratumoral IL- 12), in a phase II metastatic melanoma study with patients non-responsive to KEYTRUDA®.  

Continue reading

zoom
-

Doctor, Quit Yellen at Janet

Last month, the Chair of the Federal Reserve, Janet Yellen, made headline news when she weighed in on stock valuations in her semiannual monetary policy report. In her testimony before the Senate Banking Committee, Dr. Yellen made the following statement:

Continue reading

zoom
Dr. Holbrook Kohrt at DNA Vaccine Conference
-

Dr. Kohrt Adds Major Clout

Today I am proud to announce the appointment of Dr. Holbrook Kohrt to OncoSec’s Scientific Advisory Board. Holbrook is a brilliant physician and researcher with extensive knowledge in tumor immunology and clinical trial design.

Continue reading

zoom
-

2014 Annual Letter To OncoSec Shareholders

A Letter to Our Shareholders

This is an important moment in cancer immunotherapy and we believe OncoSec is poised to make a real impact. During this pivotal time, it is important that we outline the core fundamentals of our company and our technology, so that you as shareholders will understand why all of us here at OncoSec are excited for the future.

Continue reading

zoom
-

2014 Is Poised to be a Breakout Year for Cancer Immunotherapy

In the December 2013 issue of Science, Cancer Immunotherapy was named as the Breakthrough of the Year.   My initial reaction to this was a little shocking and wondering what finally swayed the sceptics to realize this?  Internally, we have been calling it a breakthrough for sometime, what did we mean by calling it a breakthrough in the first place?

Continue reading

-

The Battle To Make Chemo Obsolete

I had the privilege of participating in the 2013 Interface Digital Health Summit in my hometown of Vancouver, B.C.

Continue reading

zoom
-

Smart Patients and OncoSec Medical

Smart Patients is an online platform that connects cancer patients and caregivers, allowing for an exchange of knowledge and support. Co-founded by Gilles Frydman and Roni Zeiger, MD – Google’s former chief health strategist – Smart Patients is a platform where users can share stories about their personal experiences, talk about the current leading research in the field, as well as access a library of clinical trials. By combining a message board community and archive of clinical trials, cancer affected patients, friends and family have an invaluable resource in their own home.

Continue reading